PBSCs are increasingly being chosen as the mode of donation among unrelated donors. Pediatric patients, in particular, may receive very high CD34 + and CD3 + doses during unrelated PBSCT. In this work, we analyzed survival and GVHD outcomes in a cohort of 81 children who received unrelated PBSCT with uniform antithymocyte globulin (ATG)-based in vivo T-cell depletion for treatment of hematologic malignancy, with emphasis on the impact of cell dose on transplant outcomes. EFS was 61.5 ± 5.6%, with higher CD34 + dose (410.0 × 10 6 /kg) and lower patient risk status predicting improved survival in multivariate study. Cumulative incidence of relapse was 30.2 ± 5.2%; a low CD34 + dose was the only significant factor for relapse. Neither CD34 + nor CD3 + dose was a significant determinant of acute or chronic GVHD. Importance of CD34 + dose was reaffirmed in a subcohort of younger patients who received greater median cell doses than the overall cohort. In summary, for children who received unrelated PBSCT with ATG-based T-cell depletion for treatment of hematologic malignancy, the CD34 + dose was the most important factor for relapse and EFS, and neither the CD34 + nor the CD3 + dose influenced incidence of acute or chronic GVHD.
INTRODUCTION
In many countries, G-CSF-mobilized PBSCs have become an important cell source in unrelated hematopoietic cell transplantation (UHCT). The relative ease of PBSC collection has resulted in unrelated donors favoring PBSC rather than BM as their mode of donation. Consistent with this predilection for PBSC among unrelated donors, several studies have reported on unrelated PBSCT, mainly in the context of comparing important transplantrelated outcomes to BMT. [1] [2] [3] [4] [5] [6] Studies deriving from a mostly adult HCT population, including a recent randomized trial, conclude that unrelated PBSCT results in similar survival when compared with unrelated BMT, but with a greater incidence of chronic GVHD. 1, 2 However, several pediatric studies report that with antibody-based T-cell depletion, such as the use of antithymocyte globulin (ATG) or alemtuzumab (Campath), unrelated PBSCT may result in outcomes that are similar to BMT without an increased risk of GVHD, underscoring the notion that PBSC donation may be as valid an option as BM donation for children in the unrelated transplant setting. [3] [4] [5] [6] Despite the significant number of reports indicating comparable outcomes for unrelated PBSCT and BMT among pediatric patients, the literature on PBSCT in children outside the framework of comparisons with BMT is limited. For example, risk factors for both acute and chronic GVHD after PBSCT are not clear. A factor that may have a major impact on pediatric transplant outcomes is the infused cell dose, especially since collection of PBSC results in cell numbers that are far greater than those found in BM, and children, particularly infants, may receive very high cell doses per patient weight. Previous studies on unrelated HCT showed that high numbers of infused CD34 + cells may result in superior survival without increasing the risk of GVHD. 7, 8 The continued increase in the number of PBSCTs offered to children by unrelated donors stresses the need for further study on the impact of transplant variables, including cell dose, on major outcomes after unrelated PBSCT in children.
In this work, we analyzed the results of unrelated PBSCT undertaken in children with hematologic malignancies at our institution, and the risk factors for important transplant outcomes, with emphasis on the impact of cell dose on these outcomes.
MATERIALS AND METHODS

Patient cohort
The preliminary cohort consisted of 117 children and adolescents who received consecutive unrelated PBSCT at the Department of Pediatrics, The Catholic University of Korea, from January 2006 up till December 2011: 83 patients (71%) treated for hematologic malignancy and 34 patients (29%) treated for non-malignant disease. Excluding two patients with malignant disease who did not receive antibody-based T-cell depletion during conditioning, the final cohort consisted of 81 patients treated for hematologic malignancy (Table 1) . Risk status at transplant was based on modifications to previously published classification schemes. 3, 7 In brief, acute leukemia in first CR, CML in first chronic phase and myelodysplastic syndrome (MDS)-refractory anemia were considered standard risk. Acute leukemia in second CR or greater, or without complete remission, MDS with excess of blasts, juvenile myelomonocytic leukemia and secondary leukemia were considered high risk.
Transplantation procedures
Unrelated donor-patient pairs were matched according to high-resolution typing for HLA-A, -B, -C and DRB1 alleles. Fifty-seven patients (70%) showed a complete match at all 8 alleles, whereas 24 patients (30%) were mismatched: 18 patients with 1 allele or antigen mismatch (1 allele mismatch 9, 1 antigen mismatch 9) and 6 patients with 2 mismatches (2 alleles mismatch 1, 1 allele 1 antigen mismatch 3, 2 antigens mismatch 2).
Patients received disease-appropriate conditioning regimens; for example, the majority of acute lymphoblastic leukemia patients received TBIbased conditioning, whereas AML, CML and juvenile myelomonocytic leukemia patients received BU-based myeloablative conditioning.
All patients received pretransplant ATG (thymoglobulin; Genzyme, Cambridge, MA, USA) for GVHD prophylaxis as part of the conditioning regimen. ATG was given at a total dosage of 2.5 mg/kg per day during a period of 3 days (days − 3 to − 1). GVHD prophylaxis also included CYA (3 mg/kg per day intravenously initially, modified to achieve trough drug levels of 100-300 ng/mL) starting from day − 1 and four infusions of minidose MTX (5 mg/m 2 ) at days 1, 3, 6 and 11. Doses of mini-MTX were omitted for mucositis requiring narcotic analgesia. Posttransplantation G-CSF was started on day 5 and continued till the ANC exceeded 3000/mm 3 .
Study design
The day of neutrophil engraftment was defined as the first of 3 days in which the ANC was ⩾ 1000/mm 3 , and the day of platelet engraftment was defined as the first of 3 days in which the platelet count was ⩾ 50 000/mm 3 without platelet transfusions during the previous week. Acute and chronic GVHD were graded according to previously established criteria.
9,10 GVHD outcomes included the following: acute GVHD grades II-IV, overall chronic GVHD and extensive-type chronic GVHD. Survival outcomes included EFS, with relapse and death in remission considered events, as well as relapse rate and TRM (nonrelapse).
The primary objective of this work was to evaluate the impact of the following factors on GVHD, EFS and relapse: patient age and gender, risk status, HLA compatibility (high-resolution match of HLA-A, -B, -C and DRB1 vs mismatch), conditioning regimen (TBI vs non-TBI regimen), GVHD prophylaxis, donor-recipient gender (female to male vs others), CD34
+ cell dose per kilogram patient weight (CD34 + cell dose) and CD3 + cell dose per kilogram patient weight (CD3 + cell dose) (lower dose vs higher dose, based on the median dose for each cell type). Antecedent acute GVHD was also analyzed as an independent factor for chronic GVHD incidence.
As the main focus of this paper was to study the impact of CD34 + and CD3 + cell dose in children who received unrelated PBSCT, secondary analysis included the effect of cell dose in two subcohorts based on median patient age (⩽8.5 vs 48.5 years), as younger patients may receive very high cell doses in the graft, which may significantly influence transplant results. The effect of CD34 + and CD3 + cell doses on outcomes (higher or lower dose, based on the median dose in each subcohort) was analyzed for each age subcohort, as outlined previously. 8 
Statistical analysis
Correlation between infused CD34
+ and CD3 + cell doses was interpreted by calculating Spearman's correlation coefficient, as exemplified in a previous study. 11 Comparison of days to neutrophil and platelet engraftment according to cell dose was carried out according to the Mann-Whitney test. Incidence of acute and chronic GVHD, relapse rate and TRM was calculated with the cumulative incidence function. Univariate study of risk factors for acute and chronic GVHD, as well as for relapse was carried out with the Gray test, followed by Fine and Gray semiparametric proportional hazards modeling for multivariate study. For acute GVHD, death before day 100 was considered a competing risk, whereas for chronic GVHD death before day 365 was considered a competing risk. Analysis of risk factors for EFS was carried out with the Kaplan-Meier method and the log-rank test, followed by Cox proportional hazards regression modeling for multivariate study. Statistical analysis was carried out with the Statistical Package for the Social Sciences (SPSS) software version 16 (SPSS Inc., Chicago, IL, USA) and R package version 2.14.2 (R foundation for Statistical Computing, Vienna, Austria). P-values o0.05 were considered significant.
RESULTS
Cell infusion
In our unrelated PBSCT cohort, the medians of infused cell doses were as follows: TNC 16. 
+ cell dose had significantly faster engraftment of both neutrophils and platelets than recipients of lower CD34 + cell dose (Table 2) .
EFS
The 5-year EFS of the overall cohort was 61.5 ± 5.6% (51/80). Patient risk status (standard risk: 71.0 ± 6.7%; high risk: 45.0 ± 9.4%; P = 0.016), donor-recipient gender (female-to-male: 30.8 ± 12.8%; others: 68.2 ± 5.8%; P = 0.029) and CD34 + cell dose (higher dose: 78.0 ± 6.5%; lower dose: 44.7 ± 8.4%; P = 0.008; Figure 1a ) proved to be significant factors for EFS, whereas the remaining factors, including CD3 + cell dose (higher dose: 66.9 ± 7.4%; lower dose: 55.5 ± 8.4%; P = 0.458), patient age (⩽8.5 62.4 ± 7.8%, 48.5 years 60.8 ± 8.1%; P = 0.992) and HLA compatibility (match: 66.1 ± 6.4%; mismatch: 48.2 ± 11.8%; P = 0.339) remained insignificant (Supplementary Table 1 (Figure 1b ). Of the 13 male patients who received transplant from a female donor, 7 experienced relapse and 2 died in remission of causes not directly related to GVHD (fungal pneumonia 1, veno-occlusive disease 1).
In multivariate study, only a lower CD34 + cell dose (hazard ratio (HR): 2.44; 95% confidence interval (CI): 1.11-5.39; P = 0.027) and high patient risk status (HR: 2.18; 95% CI: 1.06-4.50; P = 0.034) proved to have a significantly adverse impact on EFS (Table 3 ). The overall survival of the cohort was 71.7 ± 5.2%.
Relapse and TRM Overall, 24 patients experienced relapse for a cumulative incidence of 30.2 ± 5.2%. In univariate study, patient risk status (standard risk: 21.6 ± 5.8%; high risk: 45.0 ± 9.7%; P = 0.049), and CD34 + cell dose (higher dose: 17.1 ± 6.0%; lower dose: 43.7 ± 8.2%; P = 0.016; Figure 2) were the important variables. However, multivariate study showed that only the infusion of a lower CD34 + cell dose had a significant impact on subsequent relapse (HR: 2.72; 95% CI: 1.12-6.58; P = 0.027).
Six patients died from TRM in remission, resulting in 8.3 ± 3.3% incidence. Causes of nonrelapse death included fungal pneumonia (N = 2), grade IV acute GVHD (N = 1), pneumonia in a patient with extensive chronic GVHD (N = 1), veno-occlusive disease (N = 1) and sepsis (N = 1).
Acute and chronic GVHD Forty-two patients experienced grades II-IV acute GVHD for a cumulative incidence of 51.8 ± 5.6%. None of the factors studied, including HLA compatibility (match: 49.1 ± 6.7%; mismatch: 58.3 ± 10.4%; P = 0.319), CD34 + cell dose (higher dose: 46.3 ± 7.9%; lower dose: 57.5 ± 8.0%; P = 0.608) and CD3 + cell dose (higher dose: 52.3 ± 7.7%; lower dose: 51.4 ± 8.4%; P = 0.771) affected acute GVHD incidence. Overall, only four patients were diagnosed with acute GVHD of grade III or higher giving an incidence of 4.9 ± 2.4%.
Twenty-nine patients were diagnosed with chronic GVHD, 20 of whom had the extensive form resulting in an incidence of 36.0 ± 5.4% for overall chronic GVHD and 24.7 ± 4.8% for extensive chronic GVHD. None of the factors studied, including CD34 + cell dose, CD3
+ cell dose and preceding acute GVHD, had a significant impact on the incidence of either overall chronic GVHD or the extensive form (Supplementary Tables 2 and 3) . Overall, two patients (2.5%) died from GVHD-related causes in remission.
Subcohorts based on patient age The overall cohort was divided into two subcohorts (younger (N = 41)/older (N = 40)) based on the median patient age, and survival and GVHD outcomes were analyzed according to the median CD34
+ and CD3 + cell dose for each subcohort. Similar to the overall cohort, patients in the younger age cohort who received a higher CD34 + cell dose had greater EFS than recipients of a lower cell dose (81.8 ± 8.2 vs 40.1 ± 11.7%; P = 0.016; Table 4 ). Also, CD34
+ cell dose showed borderline significance for relapse (higher dose: 18.2 ± 8.4%: lower dose: 49.4 ± 12.5%; P = 0.078). Although younger patients may receive extremely high cell doses in the graft, neither CD34 + nor CD3 + cell dose had a significant impact on acute or chronic GVHD incidence (Supplementary Table 4) .
DISCUSSION
For pediatric patients, significant disparity in donor-recipient weights may result in large doses of both CD34 + and CD3 + cells being infused during unrelated PBSCT. With the continued increase in unrelated PBSCT, a major concern then for the pediatric transplant clinician is whether such large cell doses may result in poor transplant outcomes, especially with regards to severe GVHD.
Contrary to this notion, we found that infusion of a higher CD34 + cell dose was the most significant factor for EFS, and the only significant factor related to decreased relapse in multivariate study. Although at least one previous study found no major association between infused CD34 + dose and transplant outcomes such as relapse and GVHD specifically in the PBSCT setting, 12 others conclude upon a much lower rate of relapse after higher CD34 + cell infusion. [13] [14] [15] The reasons for a lower relapse rate in recipients of a higher CD34 + dose remain unclear. One possible mechanism may be through faster immunologic recovery after transplant, and the early establishment of NK cells that mediate GVL effects. 16 Younger patients, who tend to have a better prognosis than older, adolescent patients, are more likely to receive high CD34 + doses per patient weight. Hence, patient age may confound any interpretation of the significance of cell dose. However, it is important to note that in our work patient age was not a major factor for either survival or relapse in initial univariate analysis and thus probably had limited effect on the relevance of CD34 + dose on transplant outcomes. In contrast to CD34 + dose, our data did not show a definite association between CD3 + dose and survival or relapse.
Another salient finding from our work is the lack of association between either CD34 + or CD3 + cell dose and subsequent GVHD. Previous studies found a greater incidence of extensive chronic GVHD in recipients of a higher CD34 + dose after PBSCT. 17, 18 However, in our pediatric cohort a higher CD34 + dose resulted only in the salutary effect of decreasing relapse and improving survival without increasing the risk for either acute or chronic GVHD. One factor that we believe is key to the lack of association between cell dose and GVHD was the use of rabbit ATG (2.5 mg/kg per day for 3 days) during conditioning before transplant. Several studies have previously shown that pretransplant in vivo T-cell depletion using antibody-based products such as ATG or alemtuzumab may lower the risk for acute and chronic GVHD in the unrelated transplant setting. [19] [20] [21] [22] In our work, the uniform administration of ATG before transplant most likely had a significant role in negating potential correlations between cell dose and GVHD incidence and severity.
A major concern for pediatric patients who receive unrelated PBSCT is the likelihood of young children, especially infants, receiving extremely high cell doses. To evaluate whether the high cell doses given to these patients resulted in poor outcome, we divided the overall cohort into two subcohorts according to median patient age and evaluated for outcomes according to the median CD34 + and CD3 + dose in each subcohort. As in the overall cohort, we found that recipients of a higher CD34 + dose in the younger subcohort had a significantly higher EFS. Furthermore, neither CD34 + nor CD3 + dose had an impact on either acute or chronic GVHD incidence, despite the high cell doses frequently administered to these very young patients.
We draw attention to the major limitations of our work. First, we were unable to ascertain major risk factors for severe forms of acute and chronic GVHD that may contribute to mortality after unrelated PBSCT in children. Favorable donor-recipient HLA compatibility within our cohort (66 of 81 patients matched at 7/8 or 8/8 alleles), and the low incidence of grades III-IV acute GVHD (4.9%) contributed to a less prominent role of wellestablished factors such as HLA disparity in GVHD incidence, as well as the inability to clarify the effect of other parameters in causing severe GVHD after unrelated PBSCT. In contrast to the low incidence of severe forms of acute GVHD, we note that the overall incidence of grades II-IV acute GVHD was conspicuously high at 52%, greater than was found in other studies on unrelated donor transplants in children. 6, 23 Preceding acute GVHD, however, did not significantly influence subsequent chronic GVHD incidence in our cohort. Finally, we emphasize that the CD34 + dose did not affect either EFS or relapse in the older subcohort of our analysis, in whom the median CD34 + cell dose was lower than in the younger subcohort. This finding raises the possibility that the relationship between CD34 + dose and survival is not clearly linear, but requires the CD34 + dose to be above a certain threshold to influence survival. In our analysis, the median CD34 + dose of the overall cohort (10.0 × 10 6 /kg) met the requirements of a statistically significant threshold. Such a high CD34 + cell dose may be achieved in very young PBSCT recipients, but may be much harder to procure for older children and adolescent patients transplanted with a limited number of donor aphereses. Replication of our findings in a much larger patient cohort may allow for the determination of a cell dose threshold, which is both prognostic for survival and more easily achieved.
In summary, for children who received unrelated PBSCT with ATG-based in vivo T-cell depletion for treatment of hematologic malignancy, the CD34 + dose was the most important factor for relapse and EFS, and neither the CD34 + nor the CD3 + dose influenced incidence of acute or chronic GVHD. These results were replicated in a subcohort analysis of younger patients who received higher median cell doses. Although requiring validation from a larger cohort of pediatric unrelated PBSCTs, the conclusions from this work may aid decision making and predict outcome of unrelated donor transplants carried out for very young patients when the donor selects PBSC as the cell source. Clarifying the factors responsible for severe GVHD after unrelated PBSCT may further improve the outcome of this increasingly important transplant method.
